Zenarestat

Zenarestat is an aldose reductase inhibitor. It was investigated as a treatment of diabetic neuropathy and cataract. It was developed by Fujisawa Pharmaceutical Co Ltd and was terminated in clinic phase 3 trials.

Price Not Available Please inquire Zenarestat Supplier Page

Catalog Number	112733-06-9
Alternative Name(s)	FR 74366; FR74366 FR-74366; CI-1014; FK-366; CI1014; FK366; FK 366; FK-366; Zenarestat;2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxoquinazolin-1-yl]acetic acid;FR74366;3-(2-Fluoro-4-bromobenzyl)-7-chloro-2,4(1H,3H)-dioxoquinazoline-1-acetic acid;3-[(4-Bromo-2-fluorophenyl)methyl]-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid;
Molecular Formula	C17H11BrClFN2O4
CAS#	112733-06-9
Purity	95%
Inchi	InChI=1S/C17H11BrClFN2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24)
Inchi Key	SXONDGSPUVNZLO-UHFFFAOYSA-N
Size	Please inquire
Supplier Page	https://www.bocsci.com/zenarestat-cas-112733-06-9-item-276149.html